Single-Molecule Investigation of the Binding Interface Stability of SARS-CoV‑2 Variants with ACE2

The SARS-CoV-2 pandemic spurred numerous research endeavors to comprehend the virus and mitigate its global severity. Understanding the binding interface between the virus and human receptors is pivotal to these efforts and paramount to curbing infection and transmission. Here we employ atomic force...

Full description

Saved in:
Bibliographic Details
Published inACS Nanoscience Au Vol. 4; no. 2; pp. 136 - 145
Main Authors Ray, Ankita, Minh Tran, Thu Thi, Santos Natividade, Rita dos, Moreira, Rodrigo A., Simpson, Joshua D., Mohammed, Danahe, Koehler, Melanie, L Petitjean, Simon J., Zhang, Qingrong, Bureau, Fabrice, Gillet, Laurent, Poma, Adolfo B., Alsteens, David
Format Journal Article Web Resource
LanguageEnglish
Published United States American Chemical Society 17.04.2024
American Chemical Society (ACS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The SARS-CoV-2 pandemic spurred numerous research endeavors to comprehend the virus and mitigate its global severity. Understanding the binding interface between the virus and human receptors is pivotal to these efforts and paramount to curbing infection and transmission. Here we employ atomic force microscopy and steered molecular dynamics simulation to explore SARS-CoV-2 receptor binding domain (RBD) variants and angiotensin-converting enzyme 2 (ACE2), examining the impact of mutations at key residues upon binding affinity. Our results show that the Omicron and Delta variants possess strengthened binding affinity in comparison to the Mu variant. Further, using sera from individuals either vaccinated or with acquired immunity following Delta strain infection, we assess the impact of immunity upon variant RBD/ACE2 complex formation. Single-molecule force spectroscopy analysis suggests that vaccination before infection may provide stronger protection across variants. These results underscore the need to monitor antigenic changes in order to continue developing innovative and effective SARS-CoV-2 abrogation strategies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
scopus-id:2-s2.0-85187492121
ISSN:2694-2496
2694-2496
DOI:10.1021/acsnanoscienceau.3c00060